Kazia Therapeutics Limited (KZIA) Revenue History
Annual and quarterly revenue from 1999 to present
KZIA Revenue Over Time (1999–2025)
KZIA Revenue Growth History
12 of 26 years with positive growth- FY1999 revenue growth
- N/A
- FY2000 revenue growth
- +38.4%
- FY2001 revenue growth
- +120.3%
- FY2002 revenue growth
- -66.7%
- FY2003 revenue growth
- +68.1%
- FY2004 revenue growth
- -50.4%
- FY2005 revenue growth
- +7.7%
- FY2006 revenue growth
- -23.3%
- FY2007 revenue growth
- +28.2%
- FY2008 revenue growth
- -23.3%
- FY2009 revenue growth
- -16.0%
- FY2010 revenue growth
- -11.1%
- FY2011 revenue growth
- -79.6%
- FY2012 revenue growth
- +21.0%
- FY2013 revenue growth
- -56.4%
- FY2014 revenue growth
- -91.8%
- FY2015 revenue growth
- +2.3%
- FY2016 revenue growth
- +4474.2%
- FY2017 revenue growth
- +115.9%
- FY2018 revenue growth
- -99.9%
- FY2019 revenue growth
- -88.1%
- FY2020 revenue growth
- +63038.0%
- FY2021 revenue growth
- +1436.6%
- FY2022 revenue growth
- -99.9%
- FY2023 revenue growth
- -94.5%
- FY2024 revenue growth
- +415755.9%
- FY2025 revenue growth
- -98.2%
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $20K | -99.2% |
| Q2 2025 | $22K | +445700.0% |
| Q4 2024 | $2.5M | +247999.5% |
| Q2 2024 | $5 | — |
| Q4 2023 | $1K | — |
| Q2 2023 | $0 | -100.0% |
| Q4 2022 | $0 | -100.0% |
| Q2 2022 | $10K | +754.7% |
Revenue Breakdown (FY 2025)
KZIA's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
By Geography
KZIA Revenue Analysis (1999–2025)
Current Revenue & Growth
As of June 13, 2026, Kazia Therapeutics Limited (KZIA) generated trailing twelve-month (TTM) revenue of $2.5 million, reflecting significant decline in growth of -99.2% year-over-year. The most recent quarter (Q4 2025) recorded $19,710 in revenue, down 11.6% sequentially.
Historical Growth Trajectory
KZIA's 5-year compound annual growth rate (CAGR) stands at -46.8%, indicating revenue contraction over this period. The 3-year CAGR of +61.3% exceeds the 5-year average, indicating an acceleration in the most recent period. Kazia Therapeutics Limited's highest annual revenue of $58.9 million was recorded in 2001.
Revenue by Segment
KZIA's revenue is primarily driven by Licensing Revenue (0%). The diversified mix across segments reduces dependence on any single product line, which can support more resilient revenue in downturns.
Peer Comparison
Compared to Healthcare sector peers — including NKTR (-36.2% YoY), SNDX (+396.7% YoY), and AGIO (+78.3% YoY) — KZIA has underperformed the peer group in revenue growth. Compare KZIA vs NKTR →
KZIA Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
 KZIACurrent | $3M | -99.2% | -46.8% | -33850.0% | |
 NKTR | $55M | -36.2% | -18.4% | -236.8% | |
 SNDX | $172M | +396.7% | +157.7% | -158.4% | |
 AGIO | $54M | +78.3% | - | -873.9% | |
 TGTX | $616M | +81.3% | +426.7% | 20.0% |
KZIA Historical Revenue Data (1999–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $42K | -98.2% | $42K | 100.0% | $-14,217,000 | -33850.0% |
| 2024 | $2.3M | +415755.9% | $2.3M | 100.0% | $-28,462,000 | -1233.2% |
| 2023 | $555 | -94.5% | $555 | 100.0% | $-24,123,969 | -4346661.1% |
| 2022 | $10K | -99.9% | $10K | 100.0% | $-25,399,000 | -253990.0% |
| 2021 | $15.2M | +1436.6% | $15.2M | 100.0% | $-6,376,000 | -42.0% |
| 2020 | $988K | +63038.0% | $988K | 100.0% | $-12,196,085 | -1234.3% |
| 2019 | $2K | -88.1% | $2K | 100.0% | $-8,380,000 | -535463.3% |
| 2018 | $13K | -99.9% | $13K | 100.0% | $-12,487,000 | -95262.4% |
| 2017 | $8.8M | +115.9% | $8.8M | 100.0% | $-10,852,760 | -123.5% |
| 2016 | $4.1M | +4474.2% | $4.1M | 100.0% | $-12,771,000 | -313.7% |
| 2015 | $89K | +2.3% | $89K | 100.0% | $-8,141,000 | -9147.2% |
| 2014 | $87K | -91.8% | $87K | 100.0% | $-6,401,000 | -7357.5% |
| 2013 | $1.1M | -56.4% | $1.1M | 104.2% | $-2,039,000 | -191.0% |
| 2012 | $2.5M | +21.0% | $2.5M | 100.0% | $-9,679,000 | -395.1% |
| 2011 | $2.0M | -79.6% | $2.0M | 100.0% | $-11,439,000 | -564.9% |
What if you invested $1,000 in KZIA back in 1999?
Total return with dividends reinvested · 27+ years of data
Calculate ReturnsHow much would $100/month in KZIA be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs KZIA Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationKZIA vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowKZIA — Frequently Asked Questions
Quick answers to the most common questions about buying KZIA stock.
Is KZIA's revenue growth accelerating or slowing?
KZIA revenue is declining -99.2% year-over-year. TTM revenue fell to $3M, contrasting with the 5-year CAGR of -46.8%. The reversal reflects either macro headwinds or company-specific challenges.
What is KZIA's revenue history from 1999 to 2026?
Kazia Therapeutics Limited (KZIA) revenue history spans 1999 to 2026. TTM revenue as of 2026 is $3M, growing at -99.2% YoY. The 5-year CAGR is -46.8%. Complete annual and quarterly revenue figures are available on this page, including gross profit, operating income, and margin trends.
What is KZIA's long-term revenue growth rate (CAGR)?
Kazia Therapeutics Limited's 5-year revenue CAGR of -46.8% reflects the variable nature of its business expansion. As of 2026, the current YoY growth rate of -99.2% is below this long-term average. CAGR is the most reliable measure of sustained revenue momentum for KZIA.
Why does KZIA's quarterly revenue fluctuate?
KZIA quarterly revenue can fluctuate significantly between periods. A quarter-over-quarter (QoQ) change does not always indicate a trend; comparing the same quarter year-over-year (YoY) is a more reliable signal for underlying growth. Kazia Therapeutics Limited's revenue data from 1999 to 2026 shows full historical quarterly detail on this page.
How is KZIA's revenue distributed by segment?
KZIA reports revenue broken down by product line and geographic region. The segment breakdown on this page shows which business units contribute the most to total revenue as of the latest fiscal year. Concentration in a single segment above 50% indicates category dependence, while a diversified mix signals more resilient revenue streams.
How does KZIA's revenue compare to industry peers?
Kazia Therapeutics Limited (KZIA) with TTM revenue of $3M and -99.2% YoY growth can be benchmarked against sector peers using the comparison table on this page. Revenue growth relative to peers indicates market share gains or losses. The peer section shows TTM revenue, YoY growth, and operating margin for direct comparisons.